As seen in other RZV trials in immunocompromised populations such as autologous HSCT recipients [19], patients with solid tumors [21], and patients with hematologic malignancies [16], RZV was found to be immunogenic as shown by high VRR for both humoral and cellular immune responses, as well as by anti-gE antibody GMC ratios and CD4[2+] T-cell frequency ratios. The gene discussed is CD4; the disease is hematologic disorder.